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Objectives The purpose of this study was to assess the comparative effectiveness and long-term
safety of transcatheter versus surgical closure of secundum atrial septal defects (ASD) in adults.
Background Transcatheter ASD closure has largely replaced surgery in most industrialized countries,
but long-term data comparing the 2 techniques are limited.
Methods We performed a retrospective population-based cohort study of all patients, ages 18 to 75
years, who had surgical or transcatheter ASD closure in Québec, Canada’s second-largest province,
using provincial administrative databases. Primary outcomes were long-term (5-year) reintervention
and all-cause mortality. Secondary outcomes were short-term (1-year) onset of congestive heart fail-
ure, stroke, or transient ischemic attack, and markers of health service use.
Results Of the 718 ASD closures performed between 1988 and 2005, 383 were surgical and 335
were transcatheter. The long-term reintervention rate was higher in patients with transcatheter ASD
closure (7.9% vs. 0.3% at 5 years, p  0.0038), but the majority of these reinterventions occurred in
the ﬁrst year. Long-term mortality with the transcatheter technique was not inferior to surgical ASD
closure (5.3% vs. 6.3% at 5 years, p  1.00). Secondary outcomes were similar in the 2 groups.
Conclusions Transcatheter ASD closure is associated with a higher long-term reintervention rate
and long-term mortality that is not inferior to surgery. Overall, these data support the current
practice of using transcatheter ASD closure in the majority of eligible patients and support the
decision to intervene on ASD with signiﬁcant shunts before symptoms become evident. (J Am
Coll Cardiol Intv 2013;6:497–503) © 2013 by the American College of Cardiology Foundation
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498Congenital defects of the atrial septum are common, ac-
counting for 10% to 17% of congenital heart disease (1).
Left untreated, atrial septal defects (ASD) lead to chronic
right-sided volume overload and right-sided chamber en-
largement. Current guidelines recommend that all patients
with hemodynamically significant ASD should undergo
ASD closure, regardless of symptoms, in order to prevent
long-term complications such as atrial arrhythmias, pulmo-
nary hypertension, and/or paradoxical embolism (2).
Surgical ASD closure has been practiced for over 50 years
and has excellent long-term results (3,4). For patients with
the most common type of ASD (secundum ASD), a
transcatheter option is also available. Transcatheter closure
is much less invasive than surgery, has fewer periprocedural
complications, and is associated with a shorter length of stay
(5). Approximately 80% of secundum ASD are suitable for
closure using currently available devices (6,7) and transcath-
eter closure is now the dominant technique in many
centers, despite a lack of long-
term data to support this prac-
tice (8 –10). The present study
was designed to examine tem-
poral trends in surgical versus
transcatheter ASD closure and
to compare long-term reinter-
vention and mortality rates be-
tween the 2 techniques.
Methods
Data sources. The Québec CHD
(Congenital Heart Disease) da-
tabase is a population-based data-
base of congenital heart disease
patients derived from provincial
administrative databases that con-
ain comprehensive demographic, diagnostic, and therapeutic
ecords of all patient-linked encounters in Québec, Canada’s
econd largest province (11). It was created by merging
uébec’s physician claims services database (Régie de
’Assurance Maladie du Québec) and the hospital discharge
ummary database (Med-Echo). By law, attestation of death
s sent to the Québec Health Insurance Board, who system-
tically updates the medical claims database. This makes
ocumentation of death complete in our database, whether
t occurred in or out of hospital.
Study population. Our study population consisted of all
SD patients between the ages of 18 and 75 years who had
urgical or transcatheter ASD closure (Fig. 1). To ensure
hat we had a population of patients with only secundum
SD, we excluded patients with codes for coexisting con-
enital anomalies and those who had surgical ASD closure
illed in the same day as other cardiac surgeries. We
Abbreviations
and Acronyms
ASD  atrial septal
defect(s)
CHF  congestive heart
failure
CI  confidence interval(s)
HR  hazard ratio(s)
ICD-9  International
Classification of Diseases-
Ninth Revision
OR  odds ratio(s)
PFO  patent foramen ovale
RR  rate ratio(s)
TIA  transient ischemic
attackxcluded patients with patent foramen ovale (PFO) closure dy excluding patients with stroke or transient ischemic
ttack (TIA) in the year prior to intervention. The Am-
latzer septal occluder (AGA Medical, St. Jude Medical, St.
aul, Minnesota) was the only device used for ASD closure
uring the study period.
Study design. This was a retrospective cohort study. Pa-
ients having an ASD intervention were followed from the
ay of intervention until death or end of study on December
1, 2005, whichever occurred first. Our primary outcomes
ere long-term (5-year) reintervention and all-cause mor-
ality. Our secondary outcomes were short-term (1-year)
nset of congestive heart failure (CHF), stroke or TIA, and
arkers of health service use. For each clinical secondary
utcome, we used a subsample of patients who did not have
history of that comorbidity at baseline. The study was
pproved by our institutional ethics board and the Québec
overnment agency responsible for privacy of access to
nformation.
Measurements. Baseline characteristics included age, sex,
nd the following comorbidities, measured in the 5 years
efore intervention: coronary artery disease; hypertension;
iabetes; CHF; pulmonary hypertension; and atrial fibrilla-
ion. Comorbidities were defined using codes from the
nternational Classification of Diseases-Ninth Revision
ICD-9). We also included the Charlson comorbidity index
12), an aggregate measure of patients’ comorbidities that
as been used in other epidemiologic studies using admin-
strative data (13,14).
Reintervention was defined as transcatheter ASD closure
r surgical ASD closure that occurred during an observation
eriod that started with the day following the index proce-
Figure 1. Study Flow Diagram
Schematic representation of how the study population was derived. ASD 
atrial septal defect; CHD  congenital heart disease.ure and continued for the duration of follow-up. For
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499patients who died during the follow-up period, the date of
death was taken directly from the medical claims database.
The most likely cause of death was determined by reviewing
all patient records in the medical claims and hospital
discharge databases between the day of intervention and the
time of death. The records were independently reviewed by
2 of the authors (M.K. and C.O.) and any disagreements
were resolved by consensus.
Clinical secondary outcomes were defined using ICD-9
diagnostic codes billed in the year following the index
procedure (428.0 to 428.9 for CHF, 430.0 to 435.9 for
stroke/TIA). Markers of health service use (outpatient
physician visits, emergency department visits, days spent in
a critical care unit, and echocardiograms per patient) were
also measured within 1 year of the index procedure, starting
with the first day after discharge from the index hospital-
ization.
Statistical analyses. The primary outcomes of reintervention
and mortality were compared at 30 days, 1 year, and 5 years,
using the chi-square statistic or Fisher exact test. For these
comparisons, we included only the subset of patients who
had at least 30 days, 1 year, or 5 years of follow-up. In
additional analyses for the mortality outcome, we included
all available follow-up for all patients and used Kaplan-
Meier curves and crude and adjusted (for Charlson comor-
bidity index) Cox proportional hazards regression models to
examine time to death. From these analyses, we report
log-rank statistics, hazard ratios (HRs), and 95% confidence
intervals (CIs). Due to the low number of reintervention
outcomes, the estimates from the Cox regression analysis for
reintervention were unstable and are not presented. The
Cox regressions were analyzed as intention-to-treat.
Secondary outcomes at 1-year follow-up were analyzed by
crude and adjusted logistic (clinical outcomes) and Poisson
regression models (health service use outcomes). From the
logistic regression model, we report odds ratios (ORs) and
95% CIs, whereas from the Poisson we report rate ratios
(RRs) and 95% CI. The regression models were adjusted for
the Charlson comorbidity index. All statistical analyses were
carried out using SAS statistical software (version 9.2, SAS
Institute Inc., Cary, North Carolina).
Sensitivity analyses. Given that the rate of our primary
outcomes was low, we were unable to adjust for more than
1 variable at a time. We chose to adjust for the Charlson
index because it provides a composite score of a patient’s
comorbidities. To examine the robustness of our results, we
repeated the primary analysis after adjusting for age and
pulmonary hypertension (which is not captured by the
Charlson index) and after excluding patients who had a
history of pulmonary hypertension. Given the possibility of
a cohort effect, we repeated the analysis by excluding
patients with ASD closure prior to 1998 (the year trans-
catheter closure became available).Results
Of the 718 patients with ASD closure between 1988 and
2005, 383 were closed surgically and 335 had transcatheter
closure. The number of transcatheter closures grew rapidly
after the technique was introduced, with a corresponding
decrease in the number of surgical closures (Fig. 2). The
baseline characteristics are presented in Table 1. Patients
undergoing transcatheter closure were older and had more
comorbidities. A notable exception was pulmonary hyper-
tension, which was more common in the surgical group.
The median length of follow-up was also longer in the
surgical group (10 years vs. 3 years).
Reintervention rates. There were 2 reinterventions in the
surgical group: the first was a surgical intervention that
occurred on the first post-operative day; and the second was
a transcatheter closure that occurred almost 13 years after
the initial procedure. The reintervention rate in the surgical
group was 1 of 383 (0.3%) after 30 days, and it remained
0.3% after 1 and 5 years of follow-up. The reintervention
rate in the transcatheter group was 6 of 327 (1.8%) after 30
days, 12 of 263 (4.6%) after 1 year, and 3 of 38 (7.9%) after
5 years of follow-up (p  0.053 for 30 days, p  0.0001 for
1 year, and p  0.0038 for 5 years vs. surgical closure). The
majority of reinterventions in the transcatheter group oc-
curred in the first year after closure (Fig. 3). Of the 18
transcatheter patients who required reintervention, 17
(94%) had a surgical reintervention. There were no peripro-
cedural deaths associated with reintervention in these pa-
tients. When we looked at patients who had transcatheter
ASD closure later in the study period (i.e., when operators
had more experience), there was a trend toward a lower
reintervention rate but it was not statistically significant
(data not shown).
Figure 2. ASD Closure Over Time
Absolute number of secundum atrial septal defect (ASD) closures in the
province of Québec. Reintervention procedures are not included in this
ﬁgure.
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500Mortality. There were no statistically significant differences
in mortality between surgical and transcatheter ASD closure
at 30 days (1.0% vs. 0.3%, p  0.38), 1 year (3.2% vs. 0.8%,
p  0.053), and 5 years of follow-up (6.3% vs. 5.3%,
1.00). However, transcatheter ASD closure was associ-
ted with lower long-term mortality when evaluated using
aplan-Meier curves, log-rank statistics, and HR (Fig. 4).
he crude mortality rates in the surgical group were 4 of 383
1.0%) after 30 days, 12 of 380 (3.2%) after 1 year, and 21
f 331 (6.3%) after 5 years of follow-up. The crude
ortality rates in the transcatheter group were 1 of 327
0.3%) after 30 days, 2 of 263 (0.8%) after 1 year, and 2 of
8 (5.3%) after 5 years of follow-up (p  0.38 for 30 days,
 0.053 for 1 year, and p  1.00 for 5 years vs. surgical
losure). The unadjusted HR for mortality was 0.278 (95%
I: 0.095 to 0.810) and this persisted after adjusting for the
harlson comorbidity index (HR: 0.161, 95% CI: 0.053 to
.491). The most likely cause of death for each patient who
Figure 3. Reintervention After ASD Closure
Kaplan-Meier estimates for time to ﬁrst reintervention during the ﬁrst
Table 1. Baseline Characteristics
Surgical Closure
(n  383)
Transcatheter Closure
(n  335) p Value
Age, yrs 43 (32–54) 49 (39–61) 0.001
Female 273 (71.3) 233 (69.6) 0.613
Comorbidities
Coronary artery disease 15 (4.0) 4 (1.3) 0.058
Hypertension 94 (24.8) 97 (32.0) 0.037
Diabetes 15 (4.0) 20 (6.6) 0.120
Congestive heart failure 63 (16.6) 37 (12.2) 0.106
Pulmonary hypertension 62 (16.4) 23 (7.6) 0.001
Atrial ﬁbrillation 76 (20.0) 64 (21.1) 0.731
Charlson comorbidity index 2 (0–3) 2 (0–4) 0.001
Median follow-up, yrs 10 (7–13) 3 (1–4) 0.001
Values are median (interquartile range) or n (%).s
5 years of follow-up. ASD  atrial septal defect.ied within 5 years of ASD closure is presented in Table 2.
here appears to be an increase in both procedure-related
eaths and long-term deaths in the surgical cohort. The
ncreased number of long-term deaths is likely due to the fact
hat surgical patients had longer follow-up in the database than
ranscatheter patients did.
Medical complications and health service use. In the year
ollowing ASD closure, there was no difference in the crude
ate of new-onset CHF (5.0% vs. 3.0%, p 0.30) or
troke/TIA (1.6% vs. 1.8%, p  0.99) between patients
ndergoing surgical versus transcatheter ASD closure. The
verage number of outpatient physician visits per patient
7.5 vs. 6.4, p  0.001) and the average number of critical
are days per patient (0.24 vs. 0.14, p  0.001) were higher
in the surgical cohort. There was no difference in the
average number of emergency department visits between
patients in the 2 groups (0.92 vs. 0.98, p  0.61). The
number of echocardiograms per patient was higher in the
transcatheter group (1.46 vs. 0.63, p  0.001). These data
are summarized in Figure 5.
Sensitivity analyses. Mortality findings observed in the Cox
analyses (HR: 0.278, 95% CI: 0.095 to 0.810) did not
change after adjusting for age (HR: 0.190, 95% CI: 0.065 to
0.558), history of pulmonary hypertension (HR: 0.293, 95%
CI: 0.100 to 0.859), or after excluding patients with
pulmonary hypertension (HR: 0.234, 95% CI: 0.077 to
0.711). When we excluded patients with ASD closure prior
to 1998 (the year transcatheter closure became available), we
observed a trend toward reduced mortality in the transcath-
eter group that was of borderline significance (HR: 0.283,
95% CI: 0.079 to 1.015, p  0.053). There was no
ifference in the rate of CHF (4.4% vs. 7.4%, p  0.48) or
troke/TIA (2.0% vs. 0%, p  0.58) in patients undergoing
Figure 4. Long-Term Mortality After ASD Closure
Kaplan-Meier estimates for mortality during the ﬁrst 5 years of follow-up.
ASD  atrial septal defect.urgical closure before versus after 1998.
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501Discussion
Transcatheter ASD closure has largely replaced surgery in
most industrialized countries, despite a paucity of long-term
data to support this practice. It is also recommended in
patients with significant shunts, even in the absence of
symptoms (2). We designed a population-level study to
assess the long-term outcomes of transcatheter versus sur-
gical ASD closure. We found that transcatheter closure had
a higher reintervention rate than did surgery, and long-term
mortality that was at least as good as that of surgery,
supporting the current practice of choosing transcatheter
closure whenever possible.
Our data show that the proportion of patients undergoing
transcatheter ASD closure has grown dramatically since the
technique was introduced, and the transcatheter approach is
now the dominant strategy for ASD closure in Québec,
Canada (Fig. 2). Our data also show that the absolute
Table 2. Mortality After ASD Closure
Patient
Age, yrs
Patient
Sex
Time of Death
(Days After Closure)
Transcatheter closure
63 F 2
32 F 213
61 F 904
71 F 906
Surgical closure
65 M 3
33 F 3
27 F 5
44 F 13
68 F 35
61 F 40
69 F 58
58 F 66
60 M 104
29 F 121
73 F 190
62 M 267
69 F 611
57 M 763
65 F 856
60 F 926
61 F 1,013
63 F 1,056
65 M 1,082
43 F 1,136
37 F 1,325
62 F 1,354
43 F 1,464
Most likely causes of death in patients who died within 5 years of ASD
ASD atrial septal defect(s).number of patients undergoing ASD closure has grown dsince the technique was introduced, suggesting that the
threshold for intervention may be lower now that a less-
invasive option is available. These findings are in agreement
with a U.S. study that showed an increase in the rate of
ASD/PFO closures per capita, during the same period (15).
The decision to close an ASD surgically versus using a
ranscatheter technique is primarily based on technical
actors. Transcatheter closure is favored for small ASD with
dequate septal rims, whereas surgical closure is preferred
hen the defect is close to the atrioventricular valves, the
oronary sinus, or the venae cavae. Once a decision is made
o proceed with transcatheter closure, the technical success
ate is reported to be 96% to 98% (5–7). We observed a
0-day reintervention rate of 1.8%, which is in keeping with
he literature.
Failure of the transcatheter technique may occur for
everal reasons. In some cases, there may be a problem with
tients at
Risk, n Cause of Death
334 Procedural (during index hospitalization)
291 Unknown
167 Hypoglycemia
166 Cancer
381 Procedural (during index hospitalization)
381 Procedural (during index hospitalization)
380 Procedural (during index hospitalization)
379 Procedural (pulmonary embolism)
378 Procedural (during index hospitalization)
377 Procedural (during index hospitalization)
376 Respiratory arrest
375 Cancer
373 Tuberculosis
371 Cardiac arrest
370 Cancer
369 Cancer
363 Cardiac arrest
361 Cancer
356 Unknown
354 Cancer
348 Heart failure
342 Cancer
337 Heart failure
335 Unknown
329 Pulmonary embolism
327 Cancer
319 Unknown
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502elective surgical closure at a later date. In other cases,
patients may experience a complication that will require
urgent reintervention, such as device embolization, cardiac
erforation, erosion, or rupture (16). Although our data-
ase did not allow us to identify the specific reasons for
eintervention, we found that the majority of reinterven-
ions in patients undergoing transcatheter ASD closure
ccurred in the first year, predominantly in the first 9
onths after ASD closure (Fig. 3). The reintervention
ate after 1 year was very low and was comparable to that
een with surgical closure. Our results support the rec-
mmendation in the 2008 American College of Cardiol-
gy/American Heart Association guidelines that patients
ith transcatheter ASD closure should undergo regular
chocardiographic follow-up in the first year after device
losure but only periodically thereafter (2).
We found that patients undergoing transcatheter ASD
closure had lower long-term mortality than did patients
undergoing surgical closure, when the data were analyzed
using log-rank statistics and hazard ratios (Fig. 4). This
difference remained significant after adjusting for age,
Charlson index, and history of pulmonary hypertension.
When we excluded patients with ASD closure prior to 1998
(the year transcatheter closure became available), the trend
toward reduced mortality persisted but was no longer
statistically significant. There was also no significant differ-
ence in mortality when the 2 techniques where compared
using the chi-square statistic or Fisher exact test at the
pre-specified time points of 30 days, 1 year, and 5 years.
Although there were more procedure-related deaths in the
surgical group, the majority of late deaths in both groups
appear to be unrelated to the ASD closure itself (Table 2).
Figure 5. Health Service Use
Health service use in patients undergoing surgical versus transcatheter
atrial septal defect (ASD) closure. The data are presented using rate ratios
and conﬁdence intervals. ED  emergency department.It remains possible that the differences in long-term mor- utality could be explained by unmeasured differences in the 2
study cohorts for which we cannot correct. However, given
that mortality in the transcatheter group was not worse than
that in the surgical group, our data support the current
practice of using transcatheter closure whenever technically
feasible.
Previous studies have found that patients undergoing
surgery after experiencing an adverse event related to trans-
catheter closure have mortality rates that are 15 to 20
higher than those associated with primary elective ASD
closure (16,17). We did not observe such a trend in our
study, but this may be a reflection of our low event rate.
The rationale for closing a hemodynamically significant
ASD is to prevent long-term complications such as heart
failure and stroke. One would expect that ASD closure
would provide these benefits, irrespective of the method
used to close the defect. Indeed, we did not observe a
significant difference in the rate of these secondary out-
comes between the 2 groups.
One of the advantages of transcatheter ASD closure is
that it is less invasive than surgery and is associated with a
shorter length of stay and decreased cost (18). Whether
these savings hold up in the long term remains to be
determined. We found that patients with surgical ASD
closure had more outpatient physician visits and critical care
days in the first year after closure than did transcatheter
patients. On the other hand, patients in the transcatheter
group did have higher usage of outpatient echocardiography
in the first year after closure and there was a higher rate of
reintervention in these patients.
Study limitations. Our data need to be interpreted in light
f the following: This was a retrospective study using
dministrative databases, where there is potential for mis-
lassification of diagnoses due to coding errors. We ad-
ressed this limitation by using very strict exclusion criteria.
or example, to exclude patients with coexisting congenital
eart disease lesions, we excluded patients with diagnostic
odes for those lesions as well as patients who had surgical
rocedures billed that would imply the existence of those
esions. Furthermore, when the Québec CHD database was
rst created, the authors performed manual chart audits to
etect and adjust for discrepancies between the data sources
11). Another limitation is that ICD-9 code 745.5 does not
ifferentiate between ASD and PFO. We addressed this
imitation by excluding patients who had a stroke or TIA in
he year prior to ASD closure because it would be very
nusual to close a PFO in Québec if there was no history of
ryptogenic stroke.
This was an observational study, where there is potential
or bias due to unmeasured confounding. The decision to
lose an ASD surgically versus using a transcatheter tech-
ique is primarily based on technical factors that cannot be
easured with administrative databases. However, it isnlikely that any of these factors are independently associ-
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503ated with our primary or secondary outcomes, minimizing
the potential for bias due to confounding by these factors.
There is also a possibility of residual confounding because
we were only able to adjust for 1 variable at a time. Thus, it
is possible that with higher event rates and longer follow-up,
the difference between surgery and intervention would have
been less pronounced. Nonetheless, the sensitivity analyses
we performed support our main conclusions.
Finally, in all of our analyses, we pooled together subjects
who underwent surgery between 1998 and 2005 (when the
transcatheter alternative was available) and those who un-
derwent surgery before 1998 in order to increase the sample
size and power of our analyses. These 2 groups of patients
are different because patients who undergo surgery in the
modern era (when there is a transcatheter alternative) tend
to have larger ASD or multiple fenestrations and are
therefore likely to have larger shunts. However, this decision
to pool the groups was taken after preliminary Kaplan-
Meier and log-rank analyses showed no difference in rein-
tervention and mortality between subjects in the surgical
cohort who underwent surgery before and after 1998 (data
not shown).
Conclusions
We performed a population-level study to assess the out-
comes of surgical versus transcatheter ASD closure in a
real-world setting. We found that the proportion of patients
undergoing transcatheter closure has grown dramatically
since the introduction of the technique and it has become
the dominant method for closing secundum ASD. Com-
pared with surgical closure, transcatheter ASD closure is
associated with a higher reintervention rate in the first year
and long-term mortality that is not inferior to surgery.
Secondary outcomes were similar between the 2 groups.
Overall, our data support the current practice of using
transcatheter closure in the majority of eligible patients and
support the decision to intervene on ASD with significant
shunts before symptoms become evident.
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